13C-Breath Tests in the study of microsomal liver function

European Review for Medical and Pharmacological Sciences

Volumn 8, Issue 1, 2004, Pages 33-46

  Nista, E C ^a   Fini, L ^a   Armuzzi, A ^a   Candelli, M ^a   Zocco, M A ^a   Cazzato, I A ^a   Merra, G ^a   Finizio, R ^a   Miele, L ^a   Grieco, A ^a   Gasbarrini, G ^a   Gasbarrini, A ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Breath Test; Liver; Microsomal function

Indexed keywords

4 ACETANISIDINE; ALBENDAZOLE; ALLOPURINOL; AMINOPHENAZONE; AMINOPYRIDINE; BENZODIAZEPINE DERIVATIVE; CAFFEINE; CARBON 13; CIMETIDINE; CYCLOSPORIN; CYTOCHROME P450; CYTOSTATIC AGENT; DEBRISOQUINE; DEETHYLLIDOCAINE; DIAZEPAM; DISULFIRAM; ERYTHROMYCIN; ESTROGEN; GLUCOCORTICOID; INFLUENZA VACCINE; INTERFERON; LIDOCAINE; MACROLIDE; MEPHENYTOIN; PHENACETIN; PHENOBARBITAL; PHENYTOIN; SPIRONOLACTONE; STEROID; UNINDEXED DRUG; ACETAMIDE DERIVATIVE; CARBON; DIAGNOSTIC AGENT;

ACUTE DISEASE; AGRANULOCYTOSIS; BREATH ANALYSIS; CHRONIC LIVER DISEASE; DRUG ANTAGONISM; DRUG COST; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; LIVER BLOOD FLOW; LIVER DISEASE; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER INJURY; LIVER METABOLISM; LIVER MICROSOME; QUANTITATIVE ANALYSIS; RELIABILITY; REVIEW; ENZYMOLOGY; METABOLISM;

ACETAMIDES; AMINOPYRINE; BREATH TESTS; CAFFEINE; CARBON ISOTOPES; CYTOCHROME P-450 ENZYME SYSTEM; DIAZEPAM; ERYTHROMYCIN; HUMANS; LIVER FUNCTION TESTS; MICROSOMES, LIVER; PHENACETIN;

EID: 2442686864     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Gibbs MA, Hosea NA. Factors affecting the clinical development of cytochrome p450 3A substrates. Clin Pharmacokinet 2003; 42(11): 969-984. Review.
2. Perri F, Pastore M, Annese V, Andriulli A. The aminopyrine breath test. Ital J Gastroenterol 1994; 26; 306-317.
3. Backes WL, Kelley RW. Organization of multiple cytochrome P450s with NADPH-cytochrome P450 reductase in membranes. Pharmacol Ther 2003; 98: 221-233. Review.
4. Sheweita SA. Drug-metabolizing enzymes: mechanisms and functions. Curr Drug Metab 2000; 1: 107-132. Review.
5. Lewis DF. Human cytochromes P450 associated with the phase 1 metabolism of drugs and other xenobiotics: a compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families. Curr Med Chem 2003; 10: 1955-1972.
6. Pirmohamed M, Park BK. Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology 2003; 192: 23-32.
7. Armuzzi A, Candelli M, Zocco MA, Andreoli A, De Lorenzo A, Nista EC, Miele L, Cremonini F, Cazzato IA, Grieco A, Gasbarrini G, Gasbarrini A. Review article: breth testing fot human liver function. Aliment Pharmacol Ther 2002; 16: 1977-1996.
8. Herold C, Regn S, Ganslmayer M, Ocker M, Echart EG, Schuppan D. Can quantitative test of liver function discriminate between different etiologies of liver cirrhosis? Dig Dis Sci 2002; 47: 2669-2673.
9. Coverdale SA, Samarasinghe DA, Lin R, Kench J, Byth K, Khan MH, Crewe E, Liddle C, George J, Farrell GC. Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with fibrotic change in chronic hepatitis C: value for predicting fibrotic progression. Am J Gastroenterol. 2003; 98: 1384-1390.
10. Huang YS, Lee SD, Deng JF, Wu JC, Lu RH, Lin YF, Wang JJ, Lo KJ. Measuring lidocaine metabolite -monoethylglicinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis. J Hepatol 1993; 19: 140-147.
11. 13C caffeine breath test as a non invasive, quantitative test of liver function. Hepatology 2003; 38: 1227-1236.
12. 14C]-aminopyrine. Ann Intern Med 1975; 83: 632-638.
13. Irving CS, Schoeller DA, Nakamura KI, Baker AL, Klein PD. The aminopyrine breath test as a measure of liver function. A quantitative description of its metabolic basis. J Lab Clin Med 1982; 100: 356-373.
14. Reichen J. Assessment of hepatic function with xenobiotics. Semin Liver Dis 1995; 15: 189-201.
15. Brockmoller J, Roots I. Assessment of liver metabolic function. Clin Pharmacokinet 1994; 27: 216-248.
16. Baker AL, Kotake AN, Schoeller DA. Clinical utility of breath tests for the assessment of hepatic function. Semin Liver Dis 1983; 3: 318-329.
17. Carlisle R, Galambos JT, Warren DW. The relationship between conventional liver tests, quantitative function tests, and histopathology in cirrhosis. Dig Dis Sci 1979; 24: 358-362.
18. 13C-breath test for quantitative assessment of liver function in humans. Hepatogastroenterology 1995; 42: 931-938.
19. Herold C, Heinz R, Raderspiel-Troger M, Schneider HT, Schuppan D, Hanh EG. Quantitative testing of liver function in patients with cirrhosis due to chronic hepatitis C to assess disease severity. Liver 2001; 21: 26-30.
20. Villeneuve JP, Infante-Rivard C, Ampelas M, Pomier-Layrargues G, Huet PM, Marleau D. Prognostic value of the aminopyrine breath test in cirrhotic patients. Hepatology 1986; 6: 928-931.
21. Adler M, Van Laethem J, Gilbert A, et al. Factors influencing survival at one year in patients with non biliary hepatic parenchymal cirrhosis. Dig Dis Sci 1990; 35: 1-5.
22. 14C-aminopyrine breath test compared to Child-Pugh score and serum bile acids in 84 cirrhotic patients. Digestion 1991; 50: 212-218.
23. Merkel C, Bolognesi M, Bellon S, et al. Aminopyrine breath test in the prognostic evaluation of patients with cirrhosis. Gut 1992; 33: 836-842.
24. Merkel C, Morabito A, Sacerdoti D, Bolognesi M, Angeli P, Gatta A. Updating prognosis of cirrhosis by Cox's regression model using Child-Pugh score and aminopyrine breath test as time-dependent covariates. Ital J Gastroenterol Hepatol 1998; 30: 276-282.
25. Wensing G, Lotterer E, Link I, Hahn EG, Fleig WE. Urinary sodium balance in patients with cirrhosis: relationship to quantitative parameters of liver function. Hepatology 1997; 26: 1149-1155.
26. Herold et al. Journal of gastroenterology and hepatology 2003; 18: 445-449
27. 14C) aminopyrine breath test in liver disease. Gut 1978; 19: 40-45.
28. Narducci F, Morelli A. Usefulness of aminopyrine breath test in chronic hepatitis. IRCS Med Sci 1981; 9: 493.
29. 14C) aminopyrine breath test in chronic liver disease. Dig Dis Sci 1981; 26: 1078-1083.
30. Monroe PS, Baker AL, Schneider JF, Krager PS, Klein PD, Schoeller DA. The aminopyrine breath test and serum bile acids reflect histologic severity in chronic hepatitis. Hepatology 1982; 2: 317-322.
31. Herold C, Heinz R, Niedobitek G, Schneider T, Hahn EG, Schuppan D. Quantitative testing of liver function in relation to fibrosis in patients with chronic hepatitis B and C. Liver 2001; 21: 260-265.
32. 13C-aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther 2002; 16: 717-725.
33. Herold C, Berg P, Kupfal D, et al. Parameters of microsomal and cytosolic liver function but not of liver perfusion predict portal vein velocity in noncirrhotic patients with chronic hepatitis C. Dig Dis Sci 2000; 45: 2233-2237.
34. Saunders JB, Lewis KO, Paton A. Early diagnosis of alcoholic cirrhosis by the aminopyrine breath test. Gastroenterology 1980; 79: 112-114.
35. Morelli A, Narducci F, Pelli MA, Farroni F, Vedovelli A. The relationship between aminopyrine breath test and severity of liver disease in cirrhosis. Am J Gastroenterol 1981; 76: 110-113.
36. 14C] aminopyrine in liver diseases. Dig Dis Sci 1982; 27: 49-56.
37. Schneider JF, Baker AL, Haines NW, Hatfield G, Boyer JL. Aminopyrine N-demethylation: a prognostic test of liver function in patients with alcoholic liver disease. Gastroenterology 1980; 79: 1145-1150.
38. Lewis KO, Nicholson G, Lance P, Paton A. Aminopyrine breath test in alcoholic liver disease and in patients on enzyme-inducing drugs. J Clin Pathol 1977; 30: 1040-1043.
39. Lotterer E, Hogel J, Gaus W, Fleig WE, Bircher J. Quantitative liver function tests as surrogate markers for end-points in controlled clinical trials: a retrospective feasibility study. Hepatology 1997; 26: 1426-1433.
40. Herold C, Ganslmayer M, Deynet C, Hahn EG, Schuppan D. Quantitative testing of liver function compared to prognostic scores in patients with primary biliary cirrhosis. Liver 2002; 22: 159-165.
41. Hepner GW, Vesell ES. Aminopyrine metabolism in the presence of hyperbilirubinemia due to cholestasis or hepatocellular disease. Combined use of laboratory tests to study disease-induced alterations in drug disposition. Clin Pharmacol Ther 1977; 21: 620-626.
42. Hepner GW, Uhlin SR, Lipton A, Harvey HA, Rohrer V. Abnormal aminopyrine metabolism in patients with hepatic neoplasms. Detection by breath test. J Am Med Assoc 1976; 236: 1587-1590.
43. Gill RA, Goodman MW, Golfus GR, Onstad GR, Bubrick MP. Aminopyrine breath test predicts surgical risk for patients with liver disease. Ann Surg 1983; 198: 701-704.
44. 14C]aminopyrine demethylation capacity after portocaval shunting. Comparative study in patients with and without arterialization of portal vein. Dig Dis Sci 1993; 38: 2177-2182.
45. Bollschweiler E, Schroder W, Holscher AH, Siewert JR. Preoperative risk analysis in patients with adenocarcinoma or squamous cell carcinoma of the oesophagus. Br J Surg 2000; 87: 1106-1110.
46. 14C]aminopyrine breath test. Transplant Proc 1993; 25: 2640-2641.
47. 13C. In: Goldstein S, Louvet P, Soulié E, eds. Les Isotopes Stables: Applications-Production. Lyon: CEA Editions, 1993: 239-246. 24
48. 14C-aminopyrine breath test. Br Med J 1980; 1: 279-280.
49. 13C-aminopyrine breath test. Eur J Pediatr 1982; 139: 129-134.
50. Shulman RJ, Irving CS, Boutton TW, Wong WW, Nichols BL, Klein PD. Effect of infant age on aminopyrine breath test results. Pediatr Res 1985; 19: 441-445.
51. Henderson G, Secor J, Heitman D, Schenker S. Effects of age and sex on the hepatic monoxygenase system: a correlative approach. Dev Pharmacol Ther 1986; 9: 201-216.
52. Schnegg M, Lauterburg BH. Quantitative liver function in the elderly assessed by galactose elimination capacity, aminopyrine demethylation and caffeine clearance. J Hepatol 1986; 3: 164-171.
53. 14C-aminopyrine, studied by the breath test. Digestion 1983; 28: 210-215.
54. 13C]aminopyrine breath test detects altered liver metabolism caused by low-dose oral contraceptives. Dig Dis Sci 1995; 40: 2417-2422.
55. 13C]aminopyrine breath test. Dig Dis Sci 2001; 46: 133-139.
56. Mehta S. Malnutrition and drugs: clinical implications. Dev Pharmacol Ther 1990; 5: 159-165.
57. Hepner GW, Vesell ES, Tantum KR. Reduced drug elimination in congestive heart failure. Studies using aminopyrine as a model drug. Am J Med 1978; 65: 371-376.
58. 14C aminopyrine breath test. Z Gastroenterol 1989; 49: 76-78.
59. Bircher J, Kuepfer A, Gikalow I, Preisig R. Aminopyrine demethylation measured by breath analysis in cirrhosis. Clin Pharmacol Ther 1976; 20: 484-492.
60. 14C]-aminopyrine breath test: a comparison of different forms of analysis. Br J Clin Pharmacol 1979; 8: 539-545.
61. Hepner GW, Vesell ES, Lipton A, Harvey HA, Wilkinson GR, Schenker S. Disposition of aminopyrine, antipyrine, diazepam and indocyanine green in patients with liver disease or anticonvulsant drug therapy: diazepam breath test and correlation in drug elimination. J Lab Clin Med 1977; 90: 440-456.
62. Villeneuve JP, Arsene D, Huet PM. Assessment of liver function by the aminopyrine breath test. Clin Invest Med 1983; 6: 5-9.
63. Nelson DC, Avant GR, Speeg KV, Hoyumpa AM, Schenker S. The effect of cimetidine on hepatic drug metabolism in cirrhotics. Hepatology 1985; 5: 305-309.
64. Barry M, Feely J. Allopurinol influences aminophenazone elimination. Clin Phamacokinet 1990; 47: 347-353.
65. Steiger U, Cotting J, Reichen J. Albendazole treatment of echinococcosis in humans: effect on microsomial metabolism and drug tolerance. Clin Pharmacol Ther 1990; 47: 347-353.
66. Lipton A, Hepner GW, White D, Harvey H. Decreased hepatic drug demethylation in patients receiving chemo-immunotherapy. Cancer 1978; 41: 1680-1684.
67. 14C-aminopyrine breath test values in patients with chronic hepatitis C. Aliment Pharmacol Ther 1994; 8: 353-355.
68. Kramer P, McClain CJ. Depression of aminopyrine metabolism by influenza vaccination. N Engl J Med 1981; 305: 1262-1264.
69. 14C-aminophenazone breath test in pesticide workers. Int Arch Occup Environ Health 1986; 57: 185-193.
70. Lane EA. The aminopyrine breath test for the evaluation of liver function in alcoholic patients: drug pharmacokinetics and environmental factors. Adv Alcohol Subst Abuse 1988; 7: 25-32.
71. Boersma JW. Preventie van agranulocytose tijdens het gebruik van pyrazolonederivaten, in het bijzonder van aminofenazone. Ned Tijdschr Geneskd 1973; 117: 376-383.
72. 2 breath analysis as measurement of demethylation of stable isotope labelled aminopyrine in man. Clin Chim Acta 1978; 84: 153-162.
73. Tanaka E, Breimer DD. In vivo function test of hepatic drug-oxidizing capacity in patient with liver disease. J Clin Pharm Ther 1981; 21: 53-59
74. Bonati M, Latini R, Galletti F, Young JF, Tognoni G, Garattini S. Caffeine disposition after oral doses. Clin Pharmacol 1982; 24: 93-98.
75. Jover R, Carnicer F, Sanchez Paya J, Climent E, Sirvent M, Marco JL. Salivary caffeine clearance predicts survival in patients with liver cirrhosis. Am J Gastroenterol 1997; 92: 1905-1908.
76. Zylber-Katz E, Granit L, Levy M. Relationship between caffeine concentration in plasma and saliva. Clin Pharmacol Ther 1984; 36: 133-137.
77. 13C) caffeine in man using respiratory exchange measurements. Biomed Mass Spectrom 1980;7:521-524.
78. 13C caffeine breath test as a non invasive, quantitative test of liver function. Hepatology 2003; 38: 1227-1236.
79. Lambert GH, Schoeller DA, Kotake SN, Flores C, Hay D. The effect of age, gender and sexual maturation on the caffeine breath test. Dev Pharmacol Ther 1986; 9: 375-388.
80. Herold C, Ganslmayer M, Ocker M, Zopf S, Gailer B, Hahn EG, Schuppan D. Inducibility of microsomal liver function may differentiate cirrhotic patients with maintained comparated with severely compromised liver reserve. J Gastroenterol Hepatol 2003; 18: 445-449.
81. Renner E, Wietholtz H, Huguenin P, Arnaud MJ, Preising R. Caffeine: a model compound for measuring liver function. Hepatology 1984; 4: 38-46.
82. Butler MA, Iwasaky M, Guengerich FP, Kadlubar FF. Human cytochrome P450 IA2, the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 1989; 86: 7696-7700.
83. Sonnenberg A, Koelz HR, Herz R, Benes I, Blum AL. Limited usefulness of the breath test in evaluation of drug metabolism: a study in human oral contraceptive users treated with dimethylaminoantipyrine and diazepam. Hepatogastroenterology 1980; 27: 104-108.
84. Hepner GW, Vesell ES, Lipton A, Harvey HA, Wilkinson GR, Schenker S. Disposition of aminopyrine, antipyrine, diazepam and indocyanine green in patients with liver disease or anticonvulsant drug therapy: diazepam breath test and correlation in drug elimination. J Lab Clin Med 1977; 90: 440-456.
85. Brockmoller J, Roots I. Assessment of liver function. Clin Pharmacokinet 1994; 27: 216-248.
86. 13C-methacetin for the detection of alterations in hepatic drug metabolism. In: Klein ER, Klein PD, eds. Stable Isotopes: Proceedings of the Third International Conference. New York: Academic Press, 1979: 507-516.
87. Lane EA. The aminopyrine breath test for the evaluation of liver function in alcoholic patients: drug pharmacokinetics and environmental factors. Adv Alcohol Subst Abuse 1988; 7: 25-32.
88. 13C-methacetin. Eur J Nucl Med 1985; 10:129-133.
89. 2-methacetin breath test (MBT) for hepatic function. A noninvasive approach. Hepatology 1984; 4: 1094.
90. 2-methacetin breath test (MBT): a comparative analysis. Hepatology 1984; 4: 1094.
91. 13C] methacetin breath test for evaluation of liver damage. Dig Dis Sci 1987; 32: 344-348.
92. 13C-Methacetin metabolism in patients with cirrhosis: relation to disease severity, haemoglobin content and oxygen supply. Aliment Pharmacol Ther. 2003; 17: 1559-1562.
93. 13C-methacetin breath test and oxygen supply. Aliment Pharmacol Ther 2003; 18: 1176.
94. 13C-methacetin breath test for quantitative liver function testing. Z Gastroenterol 1997; 35: 609-614.
95. 13C-methacetin breath test for quantitative noninvasive liver function analysis with an isotope-specific nondispersive infrared spectrometer in liver cirrhosis. Dtsch Med Wochenschr 1998; 123: 1467-1471.
96. 13C-methacetin breath test: isotope-selective nondispersive infrared spectrometry in comparison to isotope ratio mass spectrometry in volunteers and in patients with liver cirrhosis. Z Gastroenterol 1999; 37: 1139-1143.
97. 13C-methacetin breath test to evaluate functional capacity of hepatocyte in chronic liver disease. Digest Liver Dis 2000; 32: 226-232.
98. 13C-methacetin breath test for monitoring hepatic function in cirrhotic patients before and after liver transplantation. Aliment Pharmacol Ther 2003; 18: 785-790.
99. 14C-phenacetin breath test to measure hepatic function in men. Hepatology 1984; 4: 47-52.
100. Schoeller DA, Kotake AN, Lambert GH, Krager PS, Baker AL. Comparison of the phenacetin and aminopyrine breath test: effect of liver disease, inducers and cobaltous chloride. Hepatology 1985; 5: 276-281.
101. 13C-phenacetin metabolism. A combination of breath testand urine test of in vivo metabolites in the diagnosis of liver disease. Chem Pharm Bull 1996; 44: 1258-1260.
102. Lown K, Kolars JC, Turgeon K, Merion RM, Wrhigton SA, Watkins PB. The erythromycin breath test selectively measures P450 IIIA in patients with severe liver disease. Clin Pharmacol Ther 1992; 51: 229-232.
103. Chiou WL, Jeong HY, Wu TC, Ma C. Use of erythromycin breath test for in vivo assessment of cytochrome P450 IIIA activity and dosage individualization. Clin Pharmacol Ther 2001; 70: 305-310.
104. Guengerich FP. Characyerisation of human cytochrome P450 enzymes. FASEB J 1992; 6: 745-748.
105. 14C]erythromycin breath and urine test. Am J Physiol Gastrointest Liver Physiol 2003; 285: G470-482.
106. Schmidt LE, Rasmussen A, Kirkegaard P, Dalhoff K. Relationship between postoperative erythromycin breath test and early morbidity in liver transplant recipients. Transplantation 2003; 76: 358-363.